BofA analyst Neha Manpuria upgraded Dr. Reddy’s to Buy from Neutral with a INR 4,900 price target. Dr. Reddy’s could see outperformance over the next few quarters as its key launches and wide U.S. generics portfolio should support positive earnings momentum, the analyst tells investors.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on RDY: